{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:10:16Z","timestamp":1772118616412,"version":"3.50.1"},"reference-count":23,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2020,5,5]],"date-time":"2020-05-05T00:00:00Z","timestamp":1588636800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Hematological Oncology"],"published-print":{"date-parts":[[2020,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>We report final results of a phase II trial addressing efficacy and feasibility of lenalidomide maintenance in patients with chemosensitive relapse of diffuse large B\u2010cell lymphoma (DLBCL) not eligible for or failed after autologous stem cell transplantation (ASCT). Patients with relapsed DLBCL who achieved at least a partial response to salvage chemoimmunotherapy were enrolled and treated with lenalidomide 25\u2009mg\/day for 21 of 28\u2009days for 2\u2009years or until progression or unacceptable toxicity. Primary endpoint was 1\u2010year PFS. Forty\u2010six of 48 enrolled patients were assessable. Most patients had IPI \u22652, advanced stage and extranodal disease before the salvage treatment that led to trial registration; 28 (61%) patients were older than 70\u2009years. Lenalidomide was well tolerated. With the exception of neutropenia, grade\u20104 toxicities occurred in &lt;1% of courses. Three patients died of complications during maintenance and three died due to second cancers at 32 to 64\u2009months. There were 13 SAEs recorded in 12 patients; all these patients but two recovered. Lenalidomide was interrupted due to toxicity in other 6 patients, and 25 patients required dose reduction (transient in 21). At 1\u2009year from registration, 31 patients were progression free. After a median follow\u2010up of 65 (range 39\u2010124) months, 22 patients remain progression free, with a 5\u2010year PFS of 48%\u2009\u00b1\u20097%. The duration of response to lenalidomide was longer than response to prior treatment in 30 (65%) patients. Benefit was observed both in de novo and transformed DLBCL, germinal\u2010center\u2010B\u2010cell and nongerminal\u2010center\u2010B\u2010cell subtypes. Twenty\u2010six patients are alive (5\u2010year OS 62%\u2009\u00b1\u20097%). With the limitations of a nonrandomized design, these long\u2010term results suggest that lenalidomide maintenance might bring benefit to patients with chemosensitive relapse of DLBCL not eligible for or failed after ASCT. Lenalidomide was associated with durable disease control and was well tolerated in this elderly population. Further investigations on immunomodulatory drugs as maintenance in these high\u2010risk patients are warranted.<\/jats:p>","DOI":"10.1002\/hon.2742","type":"journal-article","created":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T10:24:02Z","timestamp":1588328642000},"page":"257-265","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Long\u2010lasting efficacy and safety of lenalidomide maintenance in patients with relapsed diffuse large B\u2010cell lymphoma who are not eligible for or failed autologous transplantation"],"prefix":"10.1002","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9606-6124","authenticated-orcid":false,"given":"Andr\u00e9s J. M.","family":"Ferreri","sequence":"first","affiliation":[{"name":"Lymphoma Unit IRCCS San Raffaele Scientific Institute  Milan Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianna","family":"Sassone","sequence":"additional","affiliation":[{"name":"Lymphoma Unit IRCCS San Raffaele Scientific Institute  Milan Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piera","family":"Angelillo","sequence":"additional","affiliation":[{"name":"Lymphoma Unit IRCCS San Raffaele Scientific Institute  Milan Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Zaja","sequence":"additional","affiliation":[{"name":"SC Ematologia Azienda Sanitaria Universitaria Integrata  Trieste Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Re","sequence":"additional","affiliation":[{"name":"Division of Hematology Spedali Civili  Brescia Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice","family":"Di Rocco","sequence":"additional","affiliation":[{"name":"Division of Hematology University \u201cLa Sapienza\u201d  Rome Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Spina","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology National Cancer Institute  Aviano Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Fabbri","sequence":"additional","affiliation":[{"name":"Division of Hematology Azienda Ospedaliera Universit\u00e0 Senese  Siena Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caterina","family":"Stelitano","sequence":"additional","affiliation":[{"name":"Division of Hematology AO Bianchi\u2010Melacrino\u2010Morelli  Reggio Calabria Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurizio","family":"Frezzato","sequence":"additional","affiliation":[{"name":"Division of Hematology San Bortolo Hospital  Vicenza Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Volpetti","sequence":"additional","affiliation":[{"name":"Clinica Ematologia Azienda Sanitaria Universitaria Integrata  Udine Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renato","family":"Zambello","sequence":"additional","affiliation":[{"name":"Division of Hematology, Azienda Ospedaliera di Padua University of Padua  Padua Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Rusconi","sequence":"additional","affiliation":[{"name":"Division of Hematology Niguarda Hospital  Milan Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"De Lorenzo","sequence":"additional","affiliation":[{"name":"Lymphoma Unit IRCCS San Raffaele Scientific Institute  Milan Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eloise","family":"Scarano","sequence":"additional","affiliation":[{"name":"Lymphoma Unit IRCCS San Raffaele Scientific Institute  Milan Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annalisa","family":"Arcari","sequence":"additional","affiliation":[{"name":"Department of Oncology and Hematology G. da Saliceto Hospital  Piacenza Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Bertoldero","sequence":"additional","affiliation":[{"name":"U.O. di Oncologia ed Ematologia Oncologica Ospedale di Mirano  Mirano Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Nonis","sequence":"additional","affiliation":[{"name":"University Center for Statistics in the Biomedical Sciences (CUSSB), Ateneo Vita\u2010Salute IRCCS San Raffaele Scientific Institute  Milan Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Calimeri","sequence":"additional","affiliation":[{"name":"Lymphoma Unit IRCCS San Raffaele Scientific Institute  Milan Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvatore","family":"Perrone","sequence":"additional","affiliation":[{"name":"Lymphoma Unit IRCCS San Raffaele Scientific Institute  Milan Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caterina","family":"Cecchetti","sequence":"additional","affiliation":[{"name":"Lymphoma Unit IRCCS San Raffaele Scientific Institute  Milan Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vittoria","family":"Tarantino","sequence":"additional","affiliation":[{"name":"Lymphoma Unit IRCCS San Raffaele Scientific Institute  Milan Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Steffanoni","sequence":"additional","affiliation":[{"name":"Lymphoma Unit IRCCS San Raffaele Scientific Institute  Milan Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Foppoli","sequence":"additional","affiliation":[{"name":"Lymphoma Unit IRCCS San Raffaele Scientific Institute  Milan Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio","family":"Ciceri","sequence":"additional","affiliation":[{"name":"Hematology and Bone Marrow Transplantation Unit, Department of Onco\u2010Hematology IRCCS San Raffaele Scientific Institute  Milan Italy"},{"name":"Vita\u2010Salute San Raffaele University  Milan Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurilio","family":"Ponzoni","sequence":"additional","affiliation":[{"name":"Vita\u2010Salute San Raffaele University  Milan Italy"},{"name":"Pathology Unit IRCCS San Raffaele Scientific Institute  Milan Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,5,5]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.1618"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.3816\/CLML.2010.n.055"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23524"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-03-769620"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.65.7163"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.95"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq626"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.26135"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa012914"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190801993470"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.090597"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(17)30016-9"},{"key":"e_1_2_8_14_1","unstructured":"National Cancer Institute. National Cancer Institute Common Toxicity Criteria version 3.0. http:\/\/ctep.cancer.gov\/"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.2403"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.10194"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2019.1639172"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_156686"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2015.1106532"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2016.213"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1080\/07357900600814490"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.72.6984"},{"issue":"2","key":"e_1_2_8_23_1","first-page":"Abstract #5","article-title":"ROBUST: First report of phase III randomized study of lenalidomide\/R\u2010CHOP (R2\u2010CHOP) vs placebo\/R\u2010CHOP in previously untreated ABC\u2010type diffuse large B\u2010cell lymphoma","volume":"37","author":"Vitolo U","year":"2019","journal-title":"Hematol Oncol"},{"issue":"2","key":"e_1_2_8_24_1","first-page":"Abstract #6","article-title":"Addition of lenalidomide to R\u2010CHOP (R2CHOP) improves outcomes in newly diagnosed diffuse large B\u2010cell lymphoma (DLBCL): first report of ECOG\u2010ACRIN1412 a randomized phase 2 US intergroup study of R2CHOP vs R\u2010CHOP","volume":"37","author":"Nowakowski GS","year":"2019","journal-title":"Hematol Oncol"}],"container-title":["Hematological Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.2742","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hon.2742","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.2742","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T06:17:27Z","timestamp":1693808247000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hon.2742"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,5]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["10.1002\/hon.2742"],"URL":"https:\/\/doi.org\/10.1002\/hon.2742","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1002\/HON.2742\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/HON.2742\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/HON.2742\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/HON.2742\/v2\/response1","asserted-by":"object"}]},"ISSN":["0278-0232","1099-1069"],"issn-type":[{"value":"0278-0232","type":"print"},{"value":"1099-1069","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,5]]},"assertion":[{"value":"2020-03-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-04-22","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-05","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}